Related Experiment Video
Updated: Mar 19, 2026
10:50
Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
8.4K
[Therapy of Antibody-Associated Autoimmune Encephalitis]
Fortschritte Der Neurologie-Psychiatrie
|June 15, 2016
Summary
Antibody-associated autoimmune encephalitis, causing seizures and neuropsychiatric issues, shows good outcomes with immunotherapy. Treatment strategies and prognosis vary by specific antibody-associated sub-forms.
Area of Science:
- Neurology
- Immunology
Background:
- Antibody-associated autoimmune encephalitis presents with diverse neurological and neuropsychiatric symptoms, including epileptic seizures.
- Recent advancements in neurology highlight the success of immunotherapies in managing these conditions.
Purpose of the Study:
- To review current therapeutic regimens for antibody-associated autoimmune encephalitis.
- To discuss the prognosis associated with different antibody-associated sub-forms.
Main Methods:
- Review of current widely used therapy regimens.
- Analysis of retrospective data for treatment recommendations.
- Examination of prognosis based on antibody-associated sub-forms.
Main Results:
- Immunotherapies and tumor therapy (when applicable) are primary treatment modalities.
- Complete remission is the main therapeutic goal.
- Treatment success and prognosis are dependent on specific antibody-associated sub-forms.
Conclusions:
- Antibody-associated autoimmune encephalitis is a treatable neurological disorder with a generally favorable prognosis.
- Therapeutic strategies require tailoring to individual antibody-associated sub-forms for optimal outcomes.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K
01:28Diphtheria
16
Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
16
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K